OTOPETRIN 3: A Small Molecule Inhibitor of IDH1 (G347741)

Target Name: OTOP3

NCBI ID: G347741

OTOP3

OTOPETRIN 3: A Small Molecule Inhibitor of IDH1

OTOPETRIN 3 (Otopetrin 3, transcript variant 1) is a drug candidate that is being studied for its potential as a treatment for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore OTOPETRIN 3 and its potential as a drug target, as well as its current status in preclinical and clinical trials.

OTOPETRIN 3 is a small molecule inhibitor of the protein IDH1, which is a key regulator of cell proliferation and survival. IDH1 has been implicated in the development and progression of various cancers, including breast, ovarian, and colorectal cancers. OTOPETRIN 3 is designed to selectively inhibit IDH1 activity and has been shown to be effective in preclinical models of these diseases.

In addition to its potential as a cancer therapeutic, OTOPETRIN 3 has also been studied for its potential as a neurodegenerative disease treatment. neurodegenerative diseases are a group of conditions that are characterized by the progressive loss of brain cells and their associated proteins. OTOPETRIN 3 has been shown to protect against neurodegenerative diseases in preclinical models, and is currently being tested in clinical trials for its potential as a treatment for Alzheimer's disease and other neurodegenerative disorders.

OTOPETRIN 3 has also been tested as a potential treatment for autoimmune disorders. Autoimmune disorders are a group of conditions in which the immune system attacks the body's own tissues and can cause a range of symptoms, including rheumatoid arthritis, lupus, and multiple sclerosis. OTOPETRIN 3 has been shown to improve symptoms in preclinical models of these disorders and is currently being tested in clinical trials for its potential as an autoimmune disease treatment.

In addition to its potential as a therapeutic, OTOPETRIN 3 has also been shown to be a potential biomarker for several diseases. OTOPETRIN 3 can be used as a diagnostic marker for neurodegenerative diseases, as it has been shown to reduce the levels of certain proteins involved in the development of these diseases. OTOPETRIN 3 can also be used as a biomarker for cancer, as it has been shown to reduce the levels of certain proteins involved in cancer growth and survival.

Despite its promising preclinical and clinical trial results, OTOPETRIN 3 is still in the early stages of development as a drug. The company that is currently developing OTOPETRIN 3 has not yet obtained regulatory approval for its use as a therapeutic or biomarker. However, the potential of OTOPETRIN 3 as a cancer, neurodegenerative disease, and autoimmune disorder treatment is a promising sign for its future development as a drug.

In conclusion, OTOPETRIN 3 is a small molecule inhibitor of the protein IDH1 that is being studied for its potential as a drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. OTOPETRIN 3 has shown promising results in preclinical and clinical trials and has the potential to be a valuable new treatment option for these diseases. Further research is needed to determine its safety and effectiveness as a drug and to establish its place as a valuable biomarker for these conditions.

Protein Name: Otopetrin 3

Functions: Proton-selective channel that specifically transports protons into cells. Proton-selective channel activity is probably required in cell types that use changes in intracellular pH for cell signaling or to regulate biochemical or developmental processes

The "OTOP3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OTOP3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets